Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant live attenuated mumps vaccine F genotype
- Development stage
- Unknown
- Lead developer
- U.S. Food & Drug Administration
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intramuscular
01
Overview
A recombinant live attenuated mumps vaccine based on the Jeryl Lynn strain but engineered to express the fusion (F) and hemagglutinin-neuraminidase (HN) proteins from circulating F or G genotypes of the mumps virus. This design aims to improve immunogenicity and efficacy against currently circulating strains that differ antigenically from older vaccine strains. The construct includes a mutation in the viral protein V gene to reduce virulence while maintaining attenuation, minimizing risks such as aseptic meningitis seen with some previous vaccines. The platform allows for rapid adaptation to new genotypes by facilitating exchange of key antigenic genes. Preclinical studies show robust immune responses and broad protection against divergent strains[1][3][4][5]. The primary indication is prevention of mumps infection.
- Other names
- F-genotype mumps virus attenuated strainrecombinant mumps virus expressing F and HN protein genes of genotype GMumps Vaccine, Live, Recombinant (F genotype)
02
Targets
MuV HN (Mumps virus hemagglutinin-neuraminidase protein)MuV-F (Mumps virus fusion protein)
Beyond the preview
Go deeper on recombinant live attenuated mumps vaccine F genotype.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant live attenuated mumps vaccine F genotype.